The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
0 thoughts on “New U.S. Inversion Rules Threaten Pfizer-Allergan Deal”
Comments are closed.